{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:17:12Z","timestamp":1790911032306,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.clinthera.2006.08.011","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T15:16:16Z","timestamp":1158678976000},"page":"1079-1106","source":"Crossref","is-referenced-by-count":129,"title":["Tigecycline: A glycylcycline antimicrobial agent"],"prefix":"10.1016","volume":"28","author":[{"given":"Thien-Ly","family":"Doan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horatio B.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhara","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Riska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.08.011_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1086\/380457","article-title":"Antimicrobial resistance trends and outbreak frequency in United States hospitals","volume":"38","author":"Diekema","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility","volume":"40","author":"Hiramatsu","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib3","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin\u2014United States, 2002","volume":"51","author":"Centers for Disease Control and Prevention (CDC)","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2006.08.011_bib4","first-page":"902","article-title":"Public health dispatch: Vancomycin-resistant Staphylococcus aureus\u2014Pennsylvania, 2002","volume":"51","author":"Miller","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2006.08.011_bib5","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1086\/430788","article-title":"Community-associated methicillin-resistant Staphylococcus aureus","author":"Weber","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib6","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.49.7.3018-3020.2005","article-title":"Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and recommendations for detection","volume":"49","author":"Bratu","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1469-0691.2002.00401.x","article-title":"Emerging carbapenemases in gram-negative aerobes","volume":"8","author":"Nordmann","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2006.08.011_bib8","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/AAC.49.8.3538-3540.2005","article-title":"First nosocomial outbreak of Pseudomonas aeruginosa producing an integronborne metallo-beta-lactamase (VIM-2) in the United States","volume":"49","author":"Lolans","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2006.08.011_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2005.01264.x","article-title":"The emergence and implications of metallo-betalactamases in gram-negative bacteria","volume":"11","author":"Walsh","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2006.08.011_bib10","author":"Infectious Diseases Society of America"},{"key":"10.1016\/j.clinthera.2006.08.011_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09546630510011810","article-title":"Tigecycline: A review of a new glycylcycline antibiotic","volume":"16","author":"Scheinfeld","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clinthera.2006.08.011_bib12","unstructured":"Tygacil [package insert]. Philadelphia, Pa: Wyeth Pharmaceuticals; 2005."},{"key":"10.1016\/j.clinthera.2006.08.011_bib13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dki248","article-title":"Tigecycline","volume":"56","author":"Pankey","year":"2005","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.clinthera.2006.08.011_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clinthera.2005.01.007","article-title":"Tigecycline: An investigational glycylcycline antimicrobial with activityagainst resistant gram-positive organisms","volume":"27","author":"Garrison","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.08.011_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","article-title":"The glycylcyclines: A comparative review with the tetracyclines","volume":"64","author":"Zhanel","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2006.08.011_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200565100-00002","article-title":"Tigecycline: A novel glycylcyline","volume":"65","author":"Rubinstein","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2006.08.011_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1368-7646(02)00051-1","article-title":"New developments in tetracycline antibiotics: Glycylcyclines and tetracycline efflux pump inhibitors","volume":"5","author":"Chopra","year":"2002","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.clinthera.2006.08.011_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1471-4892(01)00081-9","article-title":"Glycylcyclines: Third-generation tetracycline antibiotics","volume":"1","author":"Chopra","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.08.011_bib19","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-medicated ribosomal protection","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2004.03.002","article-title":"In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections","volume":"49","author":"Fritsche","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2005.06.001","article-title":"In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST program, 2004)","volume":"52","author":"Hoban","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diagmicrobio.2005.05.002","article-title":"Antimicrobial activity oftigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2005.05.005","article-title":"Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from 6 continents","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2005.05.003","article-title":"Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000\u20132004)","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2005.05.004","article-title":"Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and noso comial pneumonia","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0732-8893(99)00092-9","article-title":"Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1203 recent clinical bacterial isolates","volume":"36","author":"Gales","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2005.06.010","article-title":"Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib28","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.48.3.1034-1036.2004","article-title":"In vitro activities of tigecycline against the Bacteroides fragilis group","volume":"48","author":"Jacobus","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib29","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1128\/AAC.44.10.2747-2751.2000","article-title":"Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens","volume":"44","author":"Goldstein","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2006.08.011_bib30","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/431673","article-title":"In vitro activity of tigecycline against isolates from pa tients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections","volume":"41","author":"Bradford","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib31","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Methicillin-resistant Staphylococcus aureus (1030) collected from a recent global population: Tigecycline in vitro evaluation","author":"Bouchillon","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib32","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Vancomycin-resistant enterococci (VRE): A global problem: Evaluation of tigecycline against recent isolates from multi-centers globally","author":"Johnson","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ijantimicag.2004.07.007","article-title":"Antimicrobial activity of tigecycline (GAR936) tested against 3498 recent iso lates of Staphylococcus aureus recovered from nosocomial and community-acquired infections","volume":"24","author":"Fritsche","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2006.08.011_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diagmicrobio.2004.06.014","article-title":"Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline","volume":"50","author":"LaPlante","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/AAC.48.1.275-280.2004","article-title":"Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania","volume":"48","author":"Tenover","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jac\/dkg457","article-title":"Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center","volume":"52","author":"Bozdogan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib37","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Determining tigecycline's in vitro activity against multi-drug re sistant Enterobacteriaceae from the TEST program\u2014global data","author":"Johnson","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib38","series-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Activity of tigecycline tested against tetracycline-resistant Enterobacteriaceae","author":"Fritsche","year":"2004"},{"key":"10.1016\/j.clinthera.2006.08.011_bib39","series-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"In vitro activity of tigecycline and comparative antimicrobial agents against ampicillin-resistant Haemophilus influenzae isolates","author":"Betriu","year":"2004"},{"key":"10.1016\/j.clinthera.2006.08.011_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0924-8579(01)00355-7","article-title":"GAR-936 (9-t-butylglycylamidominocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: Preliminary guidelines and interpretive criteria","volume":"18","author":"Deshpande","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2006.08.011_bib41","series-title":"Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpretive Breakpoints: Informational Supplement\u2014Second Edition","year":"2006"},{"key":"10.1016\/j.clinthera.2006.08.011_bib42","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/AAC.49.9.3903-3909.2005","article-title":"Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method","volume":"49","author":"Bradford","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib43","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/jac\/dki386","article-title":"Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines","volume":"56","author":"Hope","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib44","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.45.9.2604-2608.2001","volume":"45","author":"Kenny","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0924-8579(00)00198-9","article-title":"In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis","volume":"16","author":"Roblin","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2006.08.011_bib46","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1128\/AAC.46.10.3164-3167.2002","article-title":"Comparison of the in vitro activity of the glycylcycline tige cycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria","volume":"46","author":"Wallace","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib48","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0149-2918(04)90070-7","article-title":"Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients","volume":"26","author":"Postier","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.08.011_bib49","series-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Population pharmacokinetics of tigecycline in phase 1 subjects","author":"van Wart","year":"2004"},{"key":"10.1016\/j.clinthera.2006.08.011_bib50","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.49.4.1629-1632.2005","article-title":"Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations","volume":"49","author":"Sun","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib51","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline","volume":"25","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2006.08.011_bib52","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Tigecycline (TGC) concentrations (Cp) in lung tissue, cere brospinal fluid (CSF), and bile of human subjects","author":"Rodvold","year":"2005"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.08.011_bib53","article-title":"Metabolic disposition of [14C]tigecycline in human volun teers following intravenous infusion","volume":"6","author":"Hoffman","year":"2004","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2006.08.011_bib54","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.49.4.1656-1659.2005","article-title":"Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib55","series-title":"Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"The effects of renal disease on the pharmacokinetics of tigecy cline (GAR-936)","author":"Troy","year":"2003"},{"key":"10.1016\/j.clinthera.2006.08.011_bib56","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Comparative pharmacodynamic activity of tigecycline (GAR-936) against quinolone resistant S. pneumoniae, methicillin-resistant S. aureus and vancomycin-resistant enterococci","author":"Garrison","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib57","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/AAC.44.4.1085-1088.2000","article-title":"Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci","volume":"44","author":"Hoellman","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib58","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"In vitro pharmacodynamics and post-antibiotic effects (PAE) of tigecycline against gram-negative bacteria","author":"Reese","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib59","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1592\/phco.20.14.219S.35046","article-title":"Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent","volume":"20","author":"Projan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2006.08.011_bib60","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/AAC.47.1.216-222.2003","article-title":"Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis","volume":"47","author":"Lefort","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib61","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.44.4.943-949.2000","article-title":"In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria","volume":"44","author":"van Ogtrop","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib62","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1592\/phco.22.17.1517.34117","article-title":"Antimicrobial activity of tigecycline (GAR-936) against Enterococccus faecium and Staphylococcus aureus used alone and in combination","volume":"22","author":"Mercier","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2006.08.011_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0732-8893(00)00193-0","article-title":"In vitro activity of GAR-936 against vancomycin-resistant entero cocci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae","volume":"38","author":"Patel","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dki477","article-title":"In vitro antibacterial activities of tigecycline in com bination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis","volume":"57","author":"Petersen","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.clinthera.2006.08.011_bib65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2005.05.006","article-title":"Pharmacokinetic\/pharmacodynamic profile for tigecycline\u2014a new glycylcycline antimicrobial agent","volume":"52","author":"Meagher","year":"2005","journal-title":"Diagn Microbiol Infect Dis."},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2006.08.011_bib66","first-page":"5333","article-title":"The pharmacokinetic and pharmacodynamic pro file of tigecycline","volume":"41","author":"Meagher","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib67","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Exposure-response analysis of the efficacy of tigecycline in patients with complicated intra-abdominal infections","author":"Passarell","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib68","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1128\/AAC.49.4.1636-1638.2005","article-title":"Presence of tetracycline resistance determinants and suscep tibility to tigecycline and minocycline","volume":"49","author":"Fluit","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib69","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from tigecycline phase 3 clinical trials for complicated skin and skin structure infections using diagnostic PCR analysis","author":"Jones","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/mdr.2000.6.277","article-title":"Mutations in the interdomain loop region of the tetA(A) tetracycline re sistance gene increase efflux of minocycline and glycylcyclines","volume":"6","author":"Tuckman","year":"2000","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.clinthera.2006.08.011_bib71","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1128\/AAC.49.5.1865-1871.2005","article-title":"A novel MATE family efflux pump contributes to the reduced suscepti bility of laboratory-derived Staphylococcus aureus mutants to tigecycline","volume":"49","author":"McAleese","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib72","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib73","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/AAC.47.2.665-669.2003","article-title":"AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis","volume":"47","author":"Visalli","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib74","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/AAC.49.2.791-793.2005","article-title":"AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib75","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/AAC.49.3.1017-1022.2005","article-title":"Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib76","series-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"AcrAB efflux-mediated decreased susceptibility to tigecycline in Enterobacter species","author":"Ruzin","year":"2004"},{"key":"10.1016\/j.clinthera.2006.08.011_bib77","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"E coli clinical isolates with decreased tigecycline suscepti bility exhibit altered expression of MarA, AcrAB and other genes","author":"Keeney","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib78","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1128\/AAC.44.11.3022-3027.2000","article-title":"Therapeutic efficacy of GAR936, a novel glycylcycline, in a rat model of experimental endocarditis","volume":"44","author":"Murphy","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib79","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dki109","article-title":"Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model","volume":"55","author":"Yin","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib80","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/AAC.47.2.533-540.2003","article-title":"Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia","volume":"47","author":"Edelstein","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2006.08.011_bib81","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/AAC.47.2.529-532.2003","article-title":"Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model","volume":"47","author":"Nannini","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib82","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib83","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijid.2005.05.003","article-title":"Efficacy and safety of tigecy cline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial","volume":"9","author":"Sacchidanand","year":"2005","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib84","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","article-title":"Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam","volume":"49","author":"Breedt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of ti gecycline versus imipenem\/cilastatin in patients with complicated intraabdominal infections","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib86","series-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Tigecycline vs imipenem\/cilastatin for treatment of complicated intra-abdominal in fections","author":"Dartois","year":"2004"},{"key":"10.1016\/j.clinthera.2006.08.011_bib87","unstructured":"Available at: http:\/\/www.clinicaltrials.gov\/ct\/search?term=tigecycline &submit=search Accessed February 10, 2006."},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2006.08.011_bib88","first-page":"5341","article-title":"The efficacy and safety of tigecycline in the treat ment of skin and skin-structure in fections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib89","series-title":"Vancocin hydrochloride","year":"2003"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2006.08.011_bib90","first-page":"5354","article-title":"The efficacy and safety of tigecycline for the treat ment ofcomplicated intra-abdominal infections: Analysis of pooled clinical trial data","volume":"41","author":"BabinchakT Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2006.08.011_bib91","series-title":"Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Pharmacokinetics, safety and tolerability of tigecycline (GAR-936) in healthy Japanese males","author":"Sesoko","year":"2002"},{"key":"10.1016\/j.clinthera.2006.08.011_bib92","series-title":"Program and abstracts of the 15th European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Pharmacokinetic\/pharmaco dynamic model of the tolerability of tigecycline in healthy volunteers","author":"Passarell","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib93","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijantimicag.2004.11.006","article-title":"Tigecycline: Clinical evidence and formulary positioning","volume":"25","author":"Nathwani","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2006.08.011_bib94","series-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Pharmacokinetics and pharmacodynamics of tigecycline and digoxin coadministered to healthy men","author":"Zimmerman","year":"2004"},{"key":"10.1016\/j.clinthera.2006.08.011_bib95","series-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Pharmacokinetics and pharmacodynamics of tigecy cline and warfarin coadministered to healthy subjects","author":"Raible","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.011_bib96","series-title":"2006 Drug Topics Red Book","year":"2006"},{"key":"10.1016\/j.clinthera.2006.08.011_sbref950","first-page":"20","article-title":"Switching to oral antibiotics: A cost-savings strategy in the hospitalized patient","volume":"8","author":"Ramirez","year":"1996","journal-title":"Drug Benefit Trends"},{"key":"10.1016\/j.clinthera.2006.08.011_sbref960","first-page":"28","article-title":"Switching to oral antibiotics: A cost-savings strategy in the hospitalized patient","volume":"8","author":"Ramirez","year":"1996","journal-title":"Drug Benefit Trends"},{"key":"10.1016\/j.clinthera.2006.08.011_sbref970","first-page":"34","article-title":"Switching to oral antibiotics: A cost-savings strategy in the hospitalized patient","volume":"8","author":"Ramirez","year":"1996","journal-title":"Drug Benefit Trends"},{"key":"10.1016\/j.clinthera.2006.08.011_bib98","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","article-title":"Tigecycline: What is it, and where should it be used?","volume":"56","author":"Livermore","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib99","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1345\/aph.18426","article-title":"Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria","volume":"33","author":"Evans","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2006.08.011_bib100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jac\/dki260","article-title":"Penetration, efflux, and intracellular activity of tigecy cline in human polymorphonuclear neutrophils (PMNs)","volume":"56","author":"Ong","year":"2005","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.clinthera.2006.08.011_bib101","series-title":"Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy [on CD-ROM]","article-title":"Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats","author":"Tombs","year":"1999"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T07:08:43Z","timestamp":1555830523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806001913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":103,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0149291806001913"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.08.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}